Lisata Therapeutics, Inc. ( (LSTA) ) has released its Q1 earnings. Here is a breakdown of the information Lisata Therapeutics, Inc. presented to its investors.
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases. The company is known for its proprietary cyclic peptide product candidate, certepetide, which enhances the penetration of anti-cancer drugs into solid tumors.
In its first-quarter 2025 earnings report, Lisata Therapeutics highlighted encouraging results from its ASCEND trial and announced that its cash runway extends into the third quarter of 2026. The company continues to advance its clinical development portfolio, particularly focusing on the development of certepetide in combination with other anti-cancer agents.
Key financial metrics for the quarter included a decrease in operating expenses to $5.8 million, down from $6.6 million in the same period last year. Research and development expenses saw a significant reduction, contributing to a net loss of $4.7 million, an improvement from the $5.4 million loss in the previous year. The company maintains a strong cash position with $25.8 million in cash, cash equivalents, and marketable securities.
Lisata’s strategic focus remains on the development of certepetide, with multiple ongoing and planned clinical trials across various solid tumor types. The company is also engaged in several research collaborations to explore the potential of certepetide in combination with other therapies.
Looking ahead, Lisata Therapeutics is poised to continue its momentum with a data-rich period anticipated for the remainder of 2025 and into 2026. The company is focused on managing its finances prudently and is optimistic about the potential regulatory advancements for certepetide.